Journal of Endocrinological Investigation

, Volume 34, Issue 2, pp e43–e51 | Cite as

Effectofrosiglitazoneonserum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: Results froma pilot phase 2 study

  • F. Bogazzi
  • G. Rossi
  • M. Lombardi
  • F. Raggi
  • C. Urbani
  • C. Sardella
  • C. Cosci
  • E. Martino
Original Articles


Objective: Current therapies for acromegaly are unsatisfactory for some patients. High-dose thiazolidinediones have been reported to reduce serum GH levels in animal models of acromegaly. The objective of the study was to evaluate the effect of increasing doses of rosiglitazone on serum GH and IGF-I concentrations in acromegalic patients. Design: Phase 2 clinical trial. Patients and methods: Five consecutive patients with active and uncontrolled acromegaly under conventional medical therapies were treated with increasing doses of rosiglitazone [4 mg/day every month, starting from 8 up to 20 mg/day] added to previous medical therapies for acromegaly. Results: Mean serum IGF-I concentrations decreased from 547±91 to 265±126 μg/l (p<0,001) during rosiglitazone treatment: 4 patients had normal serum IGF-I concentrations, and a patient had lowered serum IGF-I values, although still abnormal, at the end of the study. On the contrary, serum GH concentrations did not significantly changed during rosiglitazone therapy as well as other pituitary hormones. No relevant side effects of rosiglitazone were observed during the study period. Quantitative real time PCR and Western blotting showed that rosiglitazone lowered GH-dependent hepatic generation of IGF-I in HepG2 cell line. Conclusions: Rosiglitazone reduces serum IGF-I concentrations in patients with uncontrolled acromegaly under conventional medical therapies, likely actingonthe GH-dependent hepatic synthesisof IGF-I. Large studies are necessary to confirm the role of rosiglitazone as an adjunctive therapy for uncontrolled acromegalic patients under conventional medical therapies.


Acromegaly rosiglitazone IGF-I GH 


  1. 1.
    Ben-Shlomo A, Melmed S. Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 2008, 286: 192–8.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Higham CE, Chung TT, Lawrance J, Drake WM, Trainer PJ. Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol (Oxf) 2009, 71: 86–91.CrossRefGoogle Scholar
  3. 3.
    Colao A, Ghigo E, A.L.I.C.E. [Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education] study group. The manifesto A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) study group one year later: what to keep and what to amend? J Endocrinol Invest 2007, 30: 903–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Castinetti F, Morange I, Dubois N, et al. Does first-line surgery still have its place in the treatment of acromegaly? Ann Endocrinol (Paris) 2009, 70: 107–12.CrossRefGoogle Scholar
  5. 5.
    Ben-Shlomo A, Melmed S Acromegaly. Endocrinol Metab Clin North Am 2008, 37: 101–22.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Laws ER. Surgery for acromegaly: evolution of the techniques and outcomes. Rev Endocr Metab Disord 2008, 9: 67–70.PubMedCrossRefGoogle Scholar
  8. 8.
    Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997, 40: 225–36.PubMedCrossRefGoogle Scholar
  9. 9.
    Peacey SR, Toogood AA, Veldhuis JD, Thorner MO, Shalet SM. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J Clin Endocrinol Metab 2001, 86: 259–66.PubMedCrossRefGoogle Scholar
  10. 10.
    Castinetti F, Morange I, Dufour H, Regis J, Brue T. Radiotherapy and radiosurgery in acromegaly. Pituitary 2009, 12: 3–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004, 89: 1613–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf) 2008, 68: 473–80.CrossRefGoogle Scholar
  13. 13.
    Maiza JC, Vezzosi D, Matta M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 2007, 67: 282–9.CrossRefGoogle Scholar
  14. 14.
    Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008, 93: 2957–68.PubMedCrossRefGoogle Scholar
  15. 15.
    Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 2009, 161: 331–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000, 342: 1171–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Muller AF, Kopchick JJ, Flyvbjerg A, van der Lely AJ. Growth hormone receptor antagonists. J Clin Endocrinol Metab 2004, 89: 1503–11.PubMedCrossRefGoogle Scholar
  18. 18.
    Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007, 156: 75–82.PubMedCrossRefGoogle Scholar
  19. 19.
    Maffei P, Martini C, Pagano C, Sicolo N, Corbetti F. Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Ann Intern Med 2006, 145: 310–2.PubMedCrossRefGoogle Scholar
  20. 20.
    Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20: 649–88.PubMedGoogle Scholar
  21. 21.
    Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 2004, 25: 899–918.PubMedCrossRefGoogle Scholar
  22. 22.
    Emery MN, Leontiou C, Bonner SE, et al. PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. Clin Endocrinol (OXf) 2006, 65: 389–95.CrossRefGoogle Scholar
  23. 23.
    Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002, 8: 1281–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Occhi G, Albiger N, Berlucchi S, et al. Peroxisome proliferator-activated receptor gamma in the human pituitary gland: expression and splicing pattern in adenomas versus normal pituitary. J Neuroendocrinol 2007, 19: 552–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Winczyk K, Pawlikowski M. Immunohistochemical detection of PPARgamma receptors in the human pituitary adenomas: correlation with PCNA. Folia Histochem Cytobiol 2005, 43: 137–41.PubMedGoogle Scholar
  26. 26.
    Bogazzi F, Ultimieri F, Raggi F, et al. PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol 2004, 150: 863–75.PubMedCrossRefGoogle Scholar
  27. 27.
    Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 2003, 11: 1381–8.CrossRefGoogle Scholar
  28. 28.
    Ambrosi B, Dall’Asta C, Cannavó S, et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing’s disease. Eur J Endocrinol 2004, 151: 173–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Pecori Giraldi F, Scaroni C, Arvat E, et al. Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing’s disease. Clin Endocrinol (OXf) 2006, 64: 219–24.CrossRefGoogle Scholar
  30. 30.
    Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol in Cushing’s disease. J Clin Endocrinol Metab 2005, 90: 1340–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Bastemir M, Akin F, Yaylali GF. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly. Neuroendocrinology 2007, 86: 119–23.PubMedCrossRefGoogle Scholar
  32. 32.
    Giustina A, Barkan A, Chanson P, et al. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Clin Invest 2008, 31: 820–38.Google Scholar
  33. 33.
    Bogazzi F, Lombardi M, Strata E, et al. High prevalence of cardiac hypertrophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clin Endocrinol 2008, 68: 361–8.Google Scholar
  34. 34.
    Bogazzi F, Ultimieri F, Raggi F, et al. Growth hormone inhibits apoptosis in human colonic colon cancer cell lines: antagonistic effects of peroxisome proliferator activated receptor-gamma ligands. Endocrinology 2004, 145: 3353–62PubMedCrossRefGoogle Scholar
  35. 35.
    Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, et al. Activation of peroxisome proliferator-activated receptor γ (PPARγ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007, 148: 903–11.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Clemmons DR, Underwood LE, Ridgway EC, Kliman B, Kjellberg RN, Van Wyk JJ. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am J Med 1980, 69: 571–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Attanasio R, Barausse M, Cozzi R. Raloxifene lowers IGF-1 levels in acromegalic women. Eur J Endocrinol 2003, 148: 443–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004, 164: 2097–104.PubMedCrossRefGoogle Scholar
  39. 39.
    Meisner F, Walcher D, Gizard F, et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nodiabetic patients. Data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol 2006, 26: 845–50.PubMedCrossRefGoogle Scholar
  40. 40.
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356: 2457–71.PubMedCrossRefGoogle Scholar
  41. 41.
    Murlow CD, Cornell JE, Localio AR. Rosiglitazone: a thunderstorm from scarce and fragile data. Ann Intern Med 2007, 147: 585–7.CrossRefGoogle Scholar
  42. 42.
    Bihan H, Espinosa C, Valdes-Socin H et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 2004, 89: 5308–13.PubMedCrossRefGoogle Scholar
  43. 43.
    Colao A, Marzullo P, Lombardi G. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 2002, 146: 303–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Bogazzi F, Battolla L, Spinelli C, et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 2007, 92: 4271–7.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2011

Authors and Affiliations

  • F. Bogazzi
    • 1
  • G. Rossi
    • 2
  • M. Lombardi
    • 1
  • F. Raggi
    • 1
  • C. Urbani
    • 1
  • C. Sardella
    • 1
  • C. Cosci
    • 1
  • E. Martino
    • 1
  1. 1.Department of Endocrinology and MetabolismUniversity of PisaPisaItaly
  2. 2.Epidemiology and Biostatistics UnitInstitute of Clinical Physiology, National Research CouncilPisaItaly

Personalised recommendations